SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF
1934
(AMENDMENT NO. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement [_] CONFIDENTIAL, FOR USE OF THE
COMMISSION ONLY (AS PERMITTED BY
[X] Definitive Proxy Statement RULE 14C-5(D)(2))
[_] Definitive Additional Materials
[_] Soliciting Material Pursuant to (S)240.14a-11(c) or (S)240.14a-12
RESMED INC.
(Name of Registrant as Specified In Its Charter)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), 14a-6(i)(2)
or Item 22(a)(2) of Schedule 14A.
[_] $500 per each party to the controversy pursuant to Exchange Act Rule
14a-6(i)(3).
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing
fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
Notes:
<PAGE>
Dear Stockholder:
You are cordially invited to attend the Annual Meeting of Stockholders of
ResMed Inc, at 3.00p.m. local time, on Friday, November 6, 1998 at the KPMG
Boardroom, Level 27, 45 Clarence Street, Sydney, Australia.
This is the first time since 1994 that the Annual Meeting has been held in
Australia. The location was chosen in order to give our many Australian
stockholders an opportunity to get an update on the Company's activities, as
well as to highlight the Company's new 120,000 square foot facility in
Sydney, due for completion in January 1999. The Company's principal executive
offices are located at 10121 Carroll Canyon Road, San Diego, California 92131.
Information about the business of the meeting and the nominees for election as
directors of the Company are set forth in the Notice of Meeting and the Proxy
Statement, which are attached. This year you are asked to elect a Director of
the Company, to amend the Certificate of Incorporation to increase the number
of authorized shares of the Company's Common Stock from 15,000,000 to
50,000,000 and to effect a two-for-one stock split, and to ratify the
selection of independent auditors for fiscal year 1999.
Very truly yours,
Peter C. Farrell
President
<PAGE>
RESMED INC
_____________________
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
NOVEMBER 6, 1998
_____________________
The Annual Meeting of Stockholders of ResMed Inc. will be held at the at the
KPMG Boardroom, Level 27, 45 Clarence Street, Sydney, Australia on Friday,
November 6, 1998, at 3.00p.m. local time for the following purposes:
1. To elect a director, to serve for a three year term;
2. To amend the Certificate of Incorporation of the Company to (i) effect
a two-for-one stock split of the outstanding shares of the Company's Common
Stock and (ii) increase the number of authorized shares of the Company's
Common Stock, par value of $0.004 per share, from 15,000,000 to 50,000,000
shares;
3. To ratify the selection of auditors to examine the consolidated
financial statements of the Company for the fiscal year ending June 30, 1999;
and
4. To transact such other business as may properly come before the
meeting.
Please refer to the accompanying Proxy Statement for a more complete
description of the matters to be considered at the meeting. Only stockholders
of record at the close of business on September 8, 1998 will be entitled to
notice of, and to vote at, the 1998 Annual Meeting and any adjournment
thereof.
It is important that your shares be represented at the meeting. Even if you
plan to attend the meeting in person, please sign, date and return your proxy
form in the enclosed envelope as promptly as possible. This will not prevent
you from voting your shares in person if you attend, but will make sure that
your shares are represented in the event that you cannot attend.
PLEASE SIGN, DATE AND RETURN THE ENCLOSED PROXY PROMPTLY IN THE ENVELOPE
PROVIDED, WHICH REQUIRES NO UNITED STATES POSTAGE.
By Order of the Board of Directors,
Walter Flicker
Secretary
Dated: September 25, 1998
<PAGE>
<PAGE>
RESMED INC
_____________________
PROXY STATEMENT
_____________________
ANNUAL MEETING OF STOCKHOLDERS TO BE HELD NOVEMBER 6, 1998
GENERAL
The enclosed proxy is solicited on behalf of the Board of Directors of ResMed
Inc. (the "Company") for use at the 1998 Annual Meeting of Stockholders to be
held at 3.00p.m. on Friday, November 6, 1998 at the KPMG Boardroom, Level 27,
45 Clarence Street, Sydney, Australia (the "meeting") for the following
purposes:
1. To elect a director, to serve for a three year term;
2. To amend the Certificate of Incorporation of the Company to (i) effect
a two-for-one stock split of the outstanding shares of the Company's Common
Stock and (ii) increase the number of authorized shares of the Company's
Common Stock, par value of $0.004 per share, from 15,000,000 to 50,000,000
shares;
3. To ratify the selection of auditors to examine the consolidated
financial statements of the Company for the fiscal year ending June 30, 1999;
and
4. To transact such other business as may properly come before the
meeting.
The enclosed proxy may be revoked at any time before its exercise by giving
written notice of revocation to the Secretary of the Company. The shares
represented by proxies in the form solicited by the Board of Directors
received by the Company prior to or at the Annual Meeting will be voted at the
Annual Meeting. If a choice is specified on the proxy with respect to a
matter to be voted upon, the shares represented by the proxy will be voted in
accordance with that specification. If no choice is specified, the shares
will be voted as stated below in this Proxy Statement.
It is expected that this Proxy Statement and the accompanying form of proxy
will first be mailed to stockholders of the Company on or about October 2,
1998. The Company's Annual Report to Stockholders for 1998 is enclosed with
this Proxy Statement but does not form a part of the proxy soliciting
material. In addition, the Company's Annual Report to the Securities and
Exchange Commission on Form 10K is available from the Secretary of the
Company. The cost of soliciting proxies will be borne by the Company.
Following the original mailing of the proxy soliciting material, regular
employees of the Company may solicit proxies by mail, telephone, facsimile and
personal interview. The Company may also request brokerage firms and other
nominees or fiduciaries to forward copies of the proxy soliciting material and
the 1998 Annual Report to beneficial owners of the stock held in their names,
and the Company will reimburse them for reasonable out-of-pocket expenses
incurred in doing so.
VOTING SECURITIES AND VOTING RIGHTS
Holders of the Company's Common Stock of record as of the close of business on
September 8, 1998 (the "record date") are entitled to receive notice of and to
vote at the meeting. At the record date, the Company had outstanding
7,326,873 shares of Common Stock, the holders of which are entitled to one
vote per share.
<PAGE>
In order to constitute a quorum for the conduct of business at the Meeting, a
majority of the outstanding shares of the Company entitled to vote at the
Meeting must be represented at the Meeting. Shares represented by proxies
that reflect abstentions or "broker non-votes" (i.e. shares held by a broker
or nominee which are represented at the meeting, but with respect to which
such broker or nominee is not empowered to vote on a particular proposal) will
be counted as shares represented at the meeting for purposes of determining a
quorum.
<TABLE>
<CAPTION>
COMMON STOCK OWNERSHIP OF PRINCIPAL STOCKHOLDERS AND MANAGEMENT
The following table shows the number of shares of Common Stock which, according to
information supplied to the Company, are beneficially owned as of the record date by (i)
each director of the Company (and director nominees), (ii) the Chief Executive Officer,
(iii) each of the Named Officers as defined on page 5, (iv) each beneficial holder of
more than five percent of the outstanding common stock and (v) by all directors,
nominees and executive officers of the Company as a group. As used herein, "beneficial
ownership" means the sole or shared power to vote, or to direct the voting of, a
security, or the sole or shared investment power with respect to a security (i.e. the
power to dispose of, or to direct the disposition of, a security). A person is deemed,
as of any date, to have "beneficial ownership" of any security that the person has the
right to acquire within 60 days after that date.
<S> <C> <C>
Amount and
Nature of
Beneficial Percent of
Name of Beneficial Owner Ownership(1) Class
William Blair & Company L.L.C 1,214,000 (2) 16.6%
222 West Adams Street
Chicago IL 60606
AMVESCAP PLC 725,000(3) 9.9%
11 Devonshire Square
London EC2M 4YR
United Kingdom
Fleet Financial Group, Inc. 505,000 (4) 6.9%
1 Federal Street
Boston MA 02110
Peter C. Farrell
c/o ResMed Inc 486,940(5) 6.6%
10121 Carroll Canyon Road
San Diego CA 92131-1109
Christopher G. Roberts 112,500(6) 1.5%
Gary W. Pace 56,333(7) 0.8%
Michael A. Quinn 24,000(8) 0.3%
Donagh McCarthy 14,000(9) 0.2%
Walter Flicker 75,867(10) 1.0%
Norman A DeWitt 42,000(11) 0.6%
Victor Yerbury 7,000 0.1%
All executive officers and directors as a group (14 persons) 889,706(12) 12.1%
<FN>
(1) Except for the information based on Schedules 13G and Technimetrics, Inc. Report
6/30/98 as indicated in the footnotes hereto, beneficial ownership is as stated as of
September 8, 1998 and includes shares subject to options which are exercisable within 60
days after September 8, 1998.
- -2-
(2) Based on Technimetrics, Inc. Report 6/30/98 and a Schedule 13G filed by William
Blair & Company L.L.C, William Blair has sole dispositive and voting power and
beneficial ownership over these shares.
(3) Based on Technimetrics, Inc. Report 6/30/98 and Schedule 13G filed by AMVESCAP
PLC which has shared voting and dispositive power over these shares with certain of its
wholly-owned subsidiaries.
(4) Based on Technimetrics, Inc. Report 6/30/98 and a Schedule 13G filed by Fleet
Financial Group, Inc. which has shared voting and dispositive power over these shares
with certain of its wholly-owned subsidiaries.
(5) Includes 12,000 shares of Common Stock which may be acquired upon the exercise
of options.
(6) Includes 1,450 shares held by his wife, 95,550 shares held of record by Cabbit
Pty Ltd and 8,500 shares held by Acemed Pty Ltd, two Australian corporations controlled
by Dr Roberts and his wife. Includes 7,000 shares of common stock which may be acquired
upon the exercise of options.
(7) Includes 8,500 shares of common stock which may be acquired upon the exercise of
options.
(8) Includes 8,500 shares of common stock which may be acquired upon the exercise of
options.
(9) Includes 11,000 shares of common stock which may be acquired upon the exercise
of options.
(10) Includes 30,000 shares held by his wife, 20,000 shares held of record by
NewFolk Pty Ltd, an Australian corporation controlled by Mr Flicker and his wife.
Includes 5,867 shares of common stock which may be acquired upon the exercise of
options.
(11) Includes 20,833 shares held by his wife. Includes 8,167 shares of common stock
which may be acquired upon the exercise of options.
(12) Includes, in addition to the shares described in notes 5 through 11 above,
43,168 shares of Common Stock which may be acquired upon the exercise of options by
executive officers not named in the table. Excludes shares owned by Victor Yerbury who
resigned on July 1, 1998.
</TABLE>
The information presented is based upon the knowledge of management and, in
the case of the named individuals, upon information furnished by them.
EXECUTIVE OFFICERS
<TABLE>
<CAPTION>
The executive officers of the Company, as at September 8, 1998, are:
<S> <C> <C>
Name Age Position
Peter C Farrell 56 President and Chief Executive Officer
Christopher G Roberts 44 Executive Vice President
Mark Abourizk 41 General Counsel
Michael Berthon-Jones 46 Vice President, Clinical Research
David D'Cruz 40 Vice President, Quality Assurance and Regulatory Affairs
Norman W DeWitt 48 Vice President, U.S Marketing
Walter Flicker 43 Vice President, US Operations and Secretary
Michael D Hallett 40 Vice President, Advanced Products
William A Nicklin 46 Vice President, Manufacturing
Adrian M Smith 34 Vice President, Finance
Jonathan C Wright 48 Vice President, Corporate Marketing
</TABLE>
For a description of the business background of Doctor Farrell and Doctor
Roberts, see "Matters to be Acted Upon/Election of Directors".
- -3-
<PAGE>
Mr Abourizk joined the Company as General Counsel in July 1995. From June
1993 to June 1995, Mr Abourizk managed the Sydney office of Francis Abourizk
Lightowlers a legal partnership specializing in intellectual property matters.
From March 1989 to May 1993 Mr Abourizk was Deputy Manager of Sirotech Legal
Group, a technology transfer company. During the period from March 1986 to
February 1989, Mr Abourizk became a Senior Associate in the Intellectual
Property Group of an Australian national law firm, Corrs Pavey Whiting &
Byrne. Mr Abourizk received B.Sc. (Hons) and LL.B. degrees from Monash
University and Graduate Diploma in Intellectual Property from the University
of Melbourne. Mr Abourizk is admitted to practice before the High Court of
Australia, the Supreme Court of Victoria (Barrister and Solicitor) and the
Supreme Court of New South Wales (Solicitor).
Dr Berthon-Jones has been Vice President, Clinical Research of the Company
since July 1994. From July 1988 to June 1994, he was a research scientist at
the David Read Laboratory at the University of Sydney. During 1988, Dr
Berthon-Jones was a self-employed software consultant. From July 1985 until
June 1988, he was a senior research officer at the University of Sydney
Department of Physiology. Dr Berthon-Jones holds M.D. and Ph.D degrees from
the University of Sydney.
Mr D'Cruz has been Vice President, Quality Assurance and Regulatory Affairs
since September 1996. From May 1994 until September 1996, he served as
Director of Quality Assurance of the Company. From March 1990 to April 1994,
he worked in the Company's Electronic Product Development department. From
January 1989 to February 1990, he was employed at Royal Prince Alfred Hospital
to research the effects of surgery on the Vestibular Occular Reflex. From
April 1979 to February 1988 he was employed at Digital Equipment Corporation
as a hardware/software engineer. Mr D'Cruz holds a B.E. in Electronics from
Curtin University, Western Australia and a Master's in Biomedical Engineering
from the University of New South Wales.
Mr DeWitt has been Vice President, US Marketing since August 1997 and was
previously Vice President US Operations from October 1994. From November 1990
to September 1994, he was an attorney in private practice in Minneapolis,
Minnesota, most recently affiliated with the financial management advisory
firm of Steven, Foster & Co., Inc. and as a consultant to the Company. Prior
thereto, Mr DeWitt held positions both as an attorney and senior manager with
Westlun Companies, Inc., a real estate construction firm, from March 1988 to
October 1990. Mr DeWitt holds a B.A. from Amherst College, a J.D. from the
University of Minnesota Law School and a L.L.M. from William Mitchell College
of Law.
Mr Flicker was appointed Vice President, US Operations in August 1997. Prior
to his appointment Mr Flicker was Vice President, Corporate Development since
February 1995. From December 1989 until February 1995 he served as Vice
President, Finance of the Company and has served as Secretary of the Company
since August 1990. From July 1989 to November 1989, he was an engineering
consultant with Bio-Agrix Pty Ltd., a biomedical engineering consulting
company. From July 1988 to June 1989, Mr Flicker served as Business
Development Manager at Baxter Center for Medical Research Pty Ltd, a
subsidiary of Baxter International, Inc. From July 1984 to July 1988, Mr
Flicker served as Executive Director of the Medical Engineering Research
Association, an Australian biomedical industry association. Mr Flicker holds
a B.E. with Honors in mechanical engineering and a Master's in Biomedical
Engineering from the University of New South Wales.
- -4-
<PAGE>
Dr Hallett has been Vice President, Advanced Product Development since August
1997. From January 1996 to July 1997 Dr Hallett was Vice President, Technology
and New Business and from January 1993 to December 1995 was Vice President
European Operations. From July 1989 to December 1992, he was a Baxter
Visiting Research Fellow-Biomedical Engineering at the University of New South
Wales. From October 1986 to June 1989, Dr Hallett was a research engineer at
the Baxter Center for Medical Research, Sydney, Australia. Dr Hallett
received a B.E. in Chemical and Materials Engineering from the University of
Auckland, and a Master's and Ph.D. in Biomedical Engineering from the
University of New South Wales.
Mr Nicklin has been Vice President, Manufacturing of the Company since January
1990. From October 1987 to November 1989, he served as the Manufacturing
Director of Valuca Pty Ltd, a manufacturer of small electrical appliances.
From November 1989 to January 1990, Mr Nicklin was a consultant to Hanimex, a
manufacturer of photographic products. Mr Nicklin holds a certificate in
mechanical engineering.
Mr Smith has been Vice President, Finance since February 1995. From January
1986 through January 1995, Mr Smith was employed by Price Waterhouse
specializing in the auditing of listed public companies in the medical and
scientific field. Mr Smith holds a Bachelor of Economics from Macquarie
University and is a Certified Chartered Accountant.
Dr Wright has been Vice President, Marketing of the Company since June 1994.
From October 1991 to May 1994, he was New Business Development Manager at
Johnson and Johnson Medical Pty Ltd, a subsidiary of Johnson and Johnson, Inc.
From September 1988 to September 1991, Dr Wright was a Project Manager at
Sirotech Ltd, a technology transfer company. From May 1987, Dr Wright was a
Senior Project Leader at Vaso Products, a subsidiary of Bellara Medical
Products Ltd, Australia, a manufacturer of vascular devices. Dr Wright
received a B.Sc. degree from the University of NSW, a Ph.D. from the
University of Sydney, and a Graduate Diploma (Marketing) from the University
of Technology, Sydney.
EXECUTIVE COMPENSATION
The following table sets forth certain information regarding the annual and
long-term compensation for services in all capacities to the Company for the
fiscal years ended June 30, 1998, 1997 and 1996 of those persons who were at
June 30, 1998 (i) the chief executive officer of the Company, (ii) one of the
four other most highly compensated executive officers of the Company whose
annual salary and bonuses exceeded $100,000 or (iii) any other executive
officer who would have qualified under sections (i) or (ii) of this paragraph
but for the fact that the individual was not serving as an executive officer
of the registrant at the end of the 1998 fiscal year (collectively, the "Named
Officers").
- -5-
<PAGE>
<TABLE>
<CAPTION>
Summary Compensation Table
Long Term
Compensation
Annual Compensation Awards Payouts
Securities All Other
Underlying Compensation
Name and Principal Position Year Salary ($) Bonus ($) Options ($)(1)
<S> <C> <C> <C> <C> <C>
Peter C Farrell 1998 214,500 157,873 7,500 4,750
President and 1997 197,004 42,959 - 710
Chief Executive Officer 1996 191,505 61,804 7,500 5,362
Christopher G Roberts 1998 94,629 72,323 4,000 19,364
Executive Vice President 1997 99,072 23,362 - 28,774
1996 43,418 37,978 4,000 88,444
Victor Yerbury 1998 88,642 54,087 1,000 5,355
Vice President, Operations 1997 103,495 14,391 - 7,663
ResMed Limited (2) 1996 98,265 - 3,000 5,405
Norman W DeWitt 1998 102,550 43,242 2,500 3,948
Vice President, US Marketing 1997 97,500 22,500 - -
1996 95,000 17,569 3,500 2,944
Walter Flicker 1998 84,473 27,308 3,500 7,103
Vice President, US Operations
and Secretary (3)
<FN>
(1) These include pension plan payments made in lieu of salary.
(2) Mr Yerbury resigned on July 1, 1998.
(3) Compensation for Mr Flicker for fiscal years ending June 30, 1996 and
1997 did not exceed $100,000.
</TABLE>
- -6-
<PAGE>
STOCK OPTIONS
<TABLE>
<CAPTION>
Option Grants in Last Fiscal Year
Individual Grants
Number of % of Total Potential Realizable Value at
Securities Options Assumed Annual Rates of
Underlying Granted to Exercise or Stock Price Appreciation for
Options Employees in Base Price Option Term (2)
Name Granted (1) Fiscal Year ($/Sh) Expiration Date 5% 10%
<S> <C> <C> <C> <C> <C> <C>
Peter C Farrell 7,500 3.0% $ 24.00 August 5, 2007 $ 99,239 $ 244,431
Christopher G Roberts 4,000 1.6% 24.00 August 5, 2007 52,928 130,363
Victor Yerbury 1,000 0.4% 24.00 August 5, 2007 13,232 32,591
Norman W DeWitt 2,500 1.0% 24.00 August 5, 2007 33,080 81,477
Walter Flicker 3,500 1.4% 24.00 August 5, 2007 46,312 114,068
<FN>
(1) Options granted under the Company's 1995 Option Plan (the "Plan") are exercisable starting 12 months after the
grant date, with 33% of the shares covered thereby becoming exercisable at that time and an additional 33% of the option
shares becoming exercisable on each successive anniversary date, with all option shares exercisable beginning on the third
anniversary date. Under the terms of the Plan, this exercise schedule may be accelerated in certain specific situations.
(2) Assumed annual rates of stock appreciation for illustrative purposes only. Actual stock prices will vary from time
to time based upon market factors and the Company's financial performance. No assurance can be given that such rates will
be achieved.
</TABLE>
The following table sets forth information concerning the stock option
exercises by the Chief Executive Officer and Named Officers during the fiscal
year ended June 30, 1998 and the unexercised stock options held at June 30,
1998 by the named officers.
<TABLE>
<CAPTION>
Aggregated Option Exercises in Last Fiscal Year and FY-End Option Values
Number of Securities
Underlying Unexercised Value of Unexercised In-the
Shares Acquired Value Options at FY-End -Money Options at FY-End
Name on Exercise (#) Realized Exercisable Unexercisable Exercisable (1) / Unexercisable
<S> <C> <C> <C> <C> <C> <C>
Peter C Farrell - - 9,500 10,000 $ 301,620 $ 234,750
Christopher G Roberts - - 5,667 5,333 $ 181,610 $ 125,190
Victor Yerbury - - 8,000 2,000 $ 265,800 $ 50,780
Norman W DeWitt - - 7,333 3,667 $ 240,970 $ 88,000
Walter Flicker - - 4,700 4,500 $ 151,752 $ 104,680
<FN>
(1) Represents the amount by which the closing sales price of the Company's common stock on the Nasdaq Stock Market on
June 30, 1998 ($45.563 per share) multiplied by the number of shares to which the options apply exceeded the aggregate
exercise price of such options.
</TABLE>
- -7-
<PAGE>
REPORT OF THE COMPENSATION COMMITTEE
INTRODUCTION
Decisions regarding compensation of the Company's executives generally are
made based on recommendations by the Compensation Committee, which is composed
of two independent outside directors. The Compensation Committee decisions on
compensation of the Company's executive officers are reviewed and approved by
the full Board. Set forth below is a report submitted by Messrs Donagh
McCarthy and Michael A Quinn in their capacity as members of the Board's
Compensation Committee addressing the Company's compensation policies for
fiscal year 1998 as they affected executive officers of the Company, including
the Chief Executive Officer and the Named Officers.
GENERAL PHILOSOPHY
The Compensation Committee reviews and determines salaries, bonuses and all
other elements of the compensation packages offered to the executive officers
of the Company, including its Chief Executive Officer, and establishes the
general compensation policies of the Company.
The Company desires to attract, motivate and retain high quality employees who
will enable the Company to achieve its short and long term strategic goals and
values. The Company participates in a high-growth environment where
substantial competition exists for skilled employees. The ability of the
Company to attract, motivate and retain high caliber individuals is dependent
in large part upon the compensation packages it offers.
The Company believes that its executive compensation programs should reflect
the Company's financial and operating performance. In addition, individual
contribution to the Company's success should be supported and rewarded.
The 1993 Omnibus Budget Reconciliation Act ("OBRA") became law in August 1993.
Under the law, income tax deductions of publicly-traded companies in tax
years beginning on or after January 1 1994 may be limited to the extent total
compensation (including base salary, annual bonus, stock option exercises, and
non-qualified benefits) for certain executive officers exceeds $1 million
(less the amount of any "excess parachute-payments" as defined in Section 280G
of the Code) in any one year. Under OBRA, the deduction limit does not apply
to payments which qualify as "performance-based". To qualify as
"performance-based," compensation payments must be based solely upon the
achievement of objective performance goals and made under a plan that is
administered by a committee of outside directors. In addition, the material
terms of the plan must be disclosed to and approved by shareholders, and the
compensation committee must certify that the performance goals were achieved
before payments can be made.
The Committee intends to design the Company's compensation programs to conform
with the OBRA legislation and related regulations so that total compensation
paid to any employee will not exceed $1 million in any one year, except for
compensation payments which qualify as "performance-based." The Company may,
however, pay compensation which is not deductible in limited circumstances
when sound management of the Company so requires.
The Company's executive and key employee compensation program consists of a
base salary component, a component providing the potential for an annual
profit sharing bonus based on overall Company performance and a component
providing the opportunity to earn stock options linking the employee's
long-term financial success to that of the stockholders.
- -8-
<PAGE>
COMPENSATION
Base Salary
Officers are compensated with salary ranges that are generally based on
similar positions in companies of comparable size and complexity to the
Company. In addition, the Company utilizes industry compensation surveys in
determining compensation. The primary level of compensation is based on a
combination of years of experience and performance. The salary of all
officers is reviewed annually in June with the amount of the increases (which
take effect the following July) based on factors such as Company performance,
general economic conditions, marketplace compensation trends and individual
performance.
In fiscal year 1998, the Board approved salary increases for the named
officers as follows:
Peter C Farrell 9%
Christopher G Roberts 10%
Victor Yerbury 0%
Norman DeWitt 5%
Walter Flicker 0%
Profit Sharing Bonus
The second compensation component is a profit sharing program under the
Company's Profit Sharing Bonus Plan. Bonuses are primarily based on the
Company's annual financial performance and secondarily on the performance of
the individual. Bonuses generally range from zero to 60% of base salary. The
measures of annual financial performance used in determining the amount of
bonuses include sales growth and earnings growth.
Stock Options
The third major component of the officer's compensation consists of stock
options. The primary purpose of granting stock options is to link the
officers' financial success to that of the stockholders of the Company. The
exercise price of stock options is determined by the Compensation Committee at
the time the option is granted, but generally may not be less than the
prevailing market price of the Company's Common Stock as of the date of grant.
Options become exercisable commencing a minimum of twelve months from the
date of grant and are exercisable for a maximum period of 10 years, as
determined by the Compensation Committee.
Stock options were issued to Officers of the Company during fiscal year 1998
in accordance with the provisions of the Company's 1995 Option Plan.
CEO COMPENSATION
The compensation of Dr Farrell is based upon the performance of the Company
and the important role Dr Farrell plays within the Company as its founder,
President and Chief Executive Officer, as a member of the Boards of the
Company's principal subsidiaries and as an active participant in new product
and corporate development.
Compensation Committee of the Company's Board of Directors:
Donagh McCarthy (Chairman)
Michael A Quinn
Dated: September 8, 1998
The above report of the Compensation Committee will not be deemed to be
incorporated by reference to any filing by the Company under the Securities
Act of 1933 or the Securities Exchange Act of 1934, except to the extent that
the Company specifically incorporates the same by reference.
- -9-
<PAGE>
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The Compensation Committee of the Board of Directors is responsible for
executive compensation decisions as described above under "Board of Directors
and Committees of the Board". During fiscal year 1997, the committee
consisted of Mr Donagh McCarthy (Chairman) and Mr Michael A Quinn. Dr Farrell
did not participate in discussions or decisions regarding his compensation
package.
PERFORMANCE GRAPH
Set forth below is a line graph comparing the cumulative stockholder return on
the Company's Common Stock against the cumulative total return of the NASDAQ
Composite Index and the Standard & Poors Medical Products and Supplies Index
for the period commencing June 2, 1995 (the date the Company's Common Stock
commenced trading on the NASDAQ Stock Market) through June 30, 1998, assuming
an investment of $100 on June 2, 1995.
[GRAPHIC OMITTED]
<TABLE>
<CAPTION>
<S> <C> <C> <C> <C> <C>
June 2, 1995 June 30, 1995 June 30, 1996 June 30, 1997 June 30, 1998
------------- -------------- -------------- -------------- --------------
ResMed Inc. $ 100.00 $ 109.09 $ 140.91 $ 222.73 $ 414.21
NASDAQ Composite $ 100.00 $ 106.93 $ 135.75 $ 165.19 $ 217.05
Standard & Poors Medical
Products and Supplies $ 100.00 $ 105.19 $ 136.63 $ 179.22 $ 237.75
</TABLE>
The NASDAQ Composite Index replaces the "NASDAQ U.S. and Foreign Index"
previously used by the Company, as the latter index is no longer available to
the Company.
- -10-
<PAGE>
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
directors and officers, and persons who own more than ten percent of a
registered class of the Company's equity securities, to file with the
Securities and Exchange Commission (the "Commission") and the National
Association of Securities Dealers National Market System initial reports of
ownership and reports of change in ownership of Common Stock and other equity
securities of the Company. Officers, directors and greater than ten-percent
stockholders are required by Commission regulation to furnish the Company with
copies of all Section 16(a) forms they file.
Based solely on its review of copies of such forms received by it with respect
to fiscal 1998, or written representations from certain reporting persons, the
Company believes that during fiscal 1998 all of its directors and executive
officers and persons who own more than 10% of the Company's Common Stock have
complied with the reporting requirements of Section 16(a).
MATTERS TO BE ACTED UPON
1. Election of Directors
The Board of Directors, acting pursuant to the bylaws of the Company, has
determined that the number of directors constituting the full Board of
Directors shall be five at the present time.
The Board is divided into three classes. One such class is elected every
year at the Annual Meeting of Stockholders for a term of three years. The
class of directors whose term expires in 1998 has one member, Mr Michael A
Quinn. Accordingly, one director is to be elected at the 1998 Annual Meeting
of Stockholders, who will hold office until the 2001 Annual Meeting of
Stockholders or until the director's prior death, disability, resignation or
removal.
The Board of Directors has nominated Mr Michael A Quinn for re-election
as a director. Proxies are solicited in favor of this nominee and will be
voted for him unless otherwise specified. If Mr Quinn becomes unable or
unwilling to serve as director, it is intended that the proxies will be voted
for the election of such other person, if any, as shall be designated by the
Board of Directors.
<TABLE>
<CAPTION>
Information concerning the nominee for director and the other directors who will continue in office
after the Annual Meeting is set forth below.
<S> <C> <C>
Name Age Position with the Company
Peter C. Farrell(1) 56 President, Chief Executive Officer and Chairman of the Board of Directors
Christopher G. Roberts (2) 44 Executive Vice President and Director
Donagh McCarthy (2)(3) 51 Director
Gary W. Pace (1) 50 Director
Michael A. Quinn (3)(4) 51 Director
<FN>
(1) Term expires 2000
(2) Term expires 1999
(3) Member of Audit Committee and the Stock Option and Compensation Committee
(4) Term expires 1998
</TABLE>
- -11-
<PAGE>
Dr Farrell has been President and a director of the Company since its
inception in June 1989 and Chief Executive Officer since July 1990. From July
1984 to June 1989, Dr Farrell served as Vice President, Research and
Development at various subsidiaries of Baxter International, Inc. ("Baxter")
and from August 1985 to June 1989, he also served as Managing Director of the
Baxter Center for Medical Research Pty Ltd., a subsidiary of Baxter. From
January 1978 to December 1989, he was Foundation Director of the Center for
Biomedical Engineering at the University of New South Wales where he currently
serves as a Visiting Professor. Dr Farrell, from 1992 to 1996, was a director
of F.H. Faulding & Co. Limited, a pharmaceutical company based in South
Australia with annual revenues over $1 billion. He holds a B.E. in chemical
engineering with Honors from the University of Sydney, an S.M. in chemical
engineering from the Massachusetts Institute of Technology, a Ph.D. in
chemical engineering and bioengineering from the University of Washington,
Seattle and a D.Sc. from the University of New South Wales. Dr Farrell was
named 1998 San Diego Entrepreneur of the Year for Health Sciences.
Dr Roberts joined the Company in August 1992 as Executive Vice President.
He has been director of the Company since September 1992. He also served as
a director of the Company from August 1989 to November 1990. From February
1989 to June 1992, Dr Roberts served in various positions, most recently as
Vice President-Clinical and Regulatory Affairs, with medical device
subsidiaries of Pacific Dunlop Limited, a large multinational manufacturing
company. From January 1984 to December 1988, he served as President of BGS
Medical Corporation, a medical device company which was acquired in September
1987 by Electro Biology Inc. ("EBI"), at which time he became Vice
President-Clinical and Regulatory Affairs of EBI. Dr Roberts holds a B.E. in
chemical engineering with Honors from the University of New South Wales, a
M.B.A. from Macquarie University and a Ph.D. in biomedical engineering from
the University of New South Wales.
Mr McCarthy has been a director of the Company since November 1994. Since
September 1996 he has been President of RMS Inc., an affiliate of Baxter
Healthcare. From June 1993 until September 1996 he was the President of the
North America Renal Division of Baxter. Mr McCarthy has held various
positions at Baxter since 1982, including that of Vice President-Global
Marketing, Strategy and Product Development. Mr McCarthy received a
bachelor's degree in engineering from the National University of Ireland and a
M.B.A. from the Wharton School, University of Pennsylvania.
Dr Pace has been a director of the Company since July 1994. Dr Pace is
President and Chief Executive Officer of RTP Pharma Corp. (formerly Research
Triangle Pharmaceutical Ltd), a biopharmaceutical company working in the area
of drug delivery, since November 1994. From January 1993 to September 1994,
he was the founding President and Chief Executive Officer of Transcend
Therapeutics Inc. (formerly Free Radical Sciences Inc.), a biopharmaceutical
company. From September 1989 to January 1993, he was Senior Vice President of
Clintec International, Inc., a Baxter/Nestle joint venture and manufacturer of
clinical nutritional products. Dr Pace holds a B.Sc. with Honors from the
University of New South Wales and a Ph.D. from the Massachusetts Institute of
Technology.
Mr Quinn, a director of the Company since September 1992, has been a
management and financial consultant since February 1992. From July 1988 to
January 1992, he served as Executive Chairman of Phoenix Scientific Industries
Limited, a manufacturer of health care and scientific products. From July
1983 to June 1988, Mr Quinn was Managing Director and Company Secretary at
Memtec Limited, an industrial membrane filtration company. He currently is a
director of Heggies Bulkhaul Limited. Mr Quinn holds a B.Sc. in physics and
applied mathematics and a B.Ec. from the University of Western Australia and a
M.B.A. from Harvard University.
- -12-
<PAGE>
COMMITTEES OF THE BOARD OF DIRECTORS
The Board of Directors has two committees to assist in the management of the
affairs of the Company the Stock Option and Compensation Committee and the
Audit Committee. The Company does not have a standing Nominating Committee.
Stock Option and Compensation Committee
The Stock Option and Compensation Committee (the "Compensation Committee")
currently consists of Messrs Donagh McCarthy (Chairman) and Michael A Quinn.
The Compensation Committee administers the Company's 1995 Option Plan and 1997
Equity Participation Plan and has the authority to grant options under the
latter plan. The Compensation Committee also makes recommendations regarding
the compensation payable, including compensation under the Company's bonus
plan, to the senior executive officers of the Company.
Audit Committee
The Audit Committee currently consists of Messrs Michael A Quinn (Chairman)
and Donagh McCarthy. This committee assists the Board in fulfilling its
functions relating to corporate accounting and reporting practices and
financial and accounting controls.
Compensation Committee
The Compensation Committee met twice and the Audit Committee met four times
during fiscal year 1998. These committees also met informally by telephone
during the fiscal year as the need arose. The Board of Directors held four
meetings during fiscal year 1998.
Each director attended at least 75% of the aggregate of the total number of
meetings of the Board of Directors held during such period and the total
number of meetings held during such period by the committees of the Board of
Directors on which that director served.
Each director, who is not an employee of the Company, received an annual fee
of $10,000 for his service as a director during fiscal 1998. In addition,
each director is reimbursed for his travel expenses for attendance at all such
meetings. Directors of the Company who are not employees also hold and receive
stock options under the Company's 1995 Option Plan and 1997 Equity
Participation Plan.
Medical Advisory Committee
In addition the Company has an independent Medical Advisory Committee. The
Medical Advisory Committee comprises leading physicians in sleep medicine who
advise the board with respect to reviewing the Company's current and proposed
product lines from a medical perspective.
- -13-
<PAGE>
Vote
The Director will be elected by a favorable vote of a plurality of the
shares of voting stock present and entitled to vote, in person or by proxy, at
the Meeting. Abstentions or broker non-votes as to the election of the
director will not affect the election of the candidate receiving the plurality
of votes. Unless instructed to the contrary, the shares represented by the
proxies will be voted FOR the election of the nominee named above as a
director. Although it is anticipated that the nominee will be able to serve
as a director, should the nominee become unavailable to serve, the proxies
will be voted for such other person or persons as may be designated by the
Company's Board of Directors.
2. Approval of Amendment to Certificate of Incorporation Effecting Stock
Split and Increasing the Authorized Number of Shares of Common Stock
On August 7, 1998 and subject to the approval of the Company's
stockholders, the Board of Directors of the Company approved an amendment to
Article Fourth of the Company's Certificate of Incorporation (the
"Amendment"). If approved by the Company's stockholders at the meeting, the
Amendment would (i) effect a two-for-one stock split (the "Stock Split") of
the outstanding shares of the Company's Common Stock, par value $0.004 per
share, and (ii) increase the number of authorized shares of the Company's
Common Stock par value $0.004 per share, from 15,000,000 to 50,000,000 shares.
The Company's Certificate of Incorporation currently authorizes the
Company to issue 15,000,000 shares of Common Stock, par value $0.004, and
2,000,000 shares of Preferred Stock, par value $0.01 per share, of which
150,000 shares of Series A Junior Participating Preferred Stock, par value
$0.01 per share have been reserved for issuance pursuant to the Rights
Agreement dated as of April 23, 1997 between the Company and American Stock
Transfer and Trust Company (the "Rights Agreement").
As of the record date, of the 15,000,000 shares of Common Stock the
Company is presently authorized to issue, 7,326,873 shares were issued and
outstanding, and an aggregate of approximately 2.55 million shares were
reserved for issuance under the Company's 1995 Stock Option Plan and 1997
Equity Participation Plan. As of the record date, no shares of Preferred
Stock or Series A Junior Participating Preferred Stock were outstanding. On
September 8, 1998, the closing sales price of the Company's Common Stock on
the NASDAQ Stock Market was $44.25 per share.
Principal Purposes and Effects of the Stock Split
The Board of Directors anticipates that the increase in the number of
outstanding shares of Common Stock resulting from the Stock Split would place
the market price of the Company's Common Stock in a range more attractive to
the financial community and the investing public and may result in a broader
market for the Company's Common Stock than that which currently exists. The
decreased price level resulting from the Stock Split may encourage and
facilitate trading in the Company's Common Stock and possibly promote greater
liquidity for the Company's stockholders.
- -14-
<PAGE>
The Stock Split would double the number of issued and outstanding shares
of the Company's Common Stock. Following the Stock Split and based on the
number of shares outstanding as of the Record Date, the number of shares of
the Company's outstanding Common Stock would increase to 14,653,746 shares.
The Stock Split would not change the equity interests of the stockholders in
the Company and would not affect the relative rights of any stockholder or
result in a dilution or diminution of any stockholder's proportionate interest
in the Company. Since the Stock Split would result in each stockholder's
interest being represented by a greater number of shares, it is possible that
higher brokerage commission might be payable after the Stock Split upon a sale
or transfer of a stockholder's same relative interest in the Company's Common
Stock because that interest would be represented by a greater number of
shares.
As a result of the Amendment, the number of shares issuable under the
Company's 1997 Equity Participation Plan as well as the number of shares
issuable upon the exercise of outstanding options under the 1995 Stock Option
Plan and the 1997 Equity Participation Plan would be proportionately adjusted
to reflect the Stock Split. The exercise price of all outstanding options
would also be proportionately adjusted to reflect the Stock Split.
Also as a result of the Amendment, the Rights Agreement provides for an
automatic adjustment in the Rights which attach to the outstanding shares of
Common Stock (and to the shares of Common Stock issuable after the Stock
Split) to give effect to the Stock Split.
The Amendment would not affect the number of shares of Preferred Stock or
Series A Junior Participating Preferred Stock which the Company is authorized
to issue and would not adjust the $0.004 par value of the Company's Common
Stock. Upon effectiveness of the Stock Split, however, an amount equal to the
par value of the shares of Common Stock issued as a result of the Stock Split
would be transferred for financial accounting purposes from the Company's
additional paid-in capital account to the Company's paid-in capital account.
Tax Consequences
The Company has been advised by its tax advisors that, under current
federal income tax laws, a stockholder's receipt of additional shares of the
Company's Common Stock as a result of the Stock Split would not constitute
taxable income to the stockholder; that the cost or other tax basis to a
stockholder of each share of the Company's Common Stock held immediately prior
to the Stock Split would be divided equally between the corresponding two
shares of the Company's Common Stock held immediately after the Stock Split;
and that the holding period for each of the two shares of the Company's Common
Stock held immediately after the Stock Split would include the period for
which the corresponding one share of Common Stock was held prior to the Stock
Split. The laws of jurisdictions other than the United States may impose
income taxes on the receipt by stockholder of additional shares of Common
Stock resulting from the Stock Split. Stockholders should consult their own
tax advisors as to the federal state, local and foreign tax effects of the
Stock Split in light of their individual circumstances.
- -15-
<PAGE>
Principal Purposes and Effects of the Increase in the Authorized Number
of Shares of Common Stock
The Board of Directors believes that the increase in the authorized
number of shares of the Company's Common Stock from 15,000,000 to 50,000,000
shares is necessary to provide the Company with (i) authority to issue a
number of shares sufficient to effect the Stock Split and (ii) a reserve for
shares to be issued under the Company's stock option and other stock related
incentive and benefit plans and in connection with any future stock dividends
or stock splits, financing, acquisitions, management incentive or employee
benefit plans and for other general corporate purposes. No further action by
stockholders would be necessary prior to the issuance of additional shares of
the Company's Common Stock except as may be required by law or by the
applicable regulations of the NASDAQ Stock Market.
The existence of additional authorized shares of Common Stock could have the
effect of rendering more difficult or discouraging hostile takeover attempts.
The Company is not aware of any existing or planned effort on the part of any
party to accumulate material amounts of voting stock, or to acquire the
Company by means of a merger, tender offer, solicitation of proxies in
opposition to management or otherwise, or to change the Company's management,
nor is the Company aware of any person having made any offer to acquire the
voting stock or assets of the Company.
The Board of Directors has no present plans for issuing any of the
additional shares of Common Stock which would be authorized by the Amendment
except as would be required in connection with the Stock Split and as would be
required in connection with Common Stock presently reserved for issuance and
exercise under the Company's 1995 Stock Option Plan and 1997 Equity
Participation Plan.
The proposed additional shares of Common Stock would be a part of the
existing class of the Company's Common Stock and, if and when issued, would
have the same rights and privileges as the shares of Common Stock presently
issued and outstanding.
Delivery of Additional Share Certificates
The Amendment would become effective upon the filing with the Delaware
Secretary of State of a Certificate of Amendment to the Company's Certificate
of Incorporation. If the Amendment is approved by the required vote of the
Company's stockholders, the Company intends to file the Certificate of
Amendment as soon as practicable after such approval is obtained and expects
that the filing would be made on or about November 6, 1998. Each stockholder
of record as of the close of business on the date of such filing (the
"Effective Date") would receive as soon as practicable after the Effective
Date an additional stock certificate representing one additional share of the
Company's Common Stock for each share of the Company's Common Stock held by
such stockholder as of the Effective Date. For example, if a stockholder
owned 100 shares of the Company's Common Stock on the Effective Date, the
Company would mail to the stockholder a share certificate for 100 additional
shares and the stockholder would then be the owner of 200 shares of the
Company's Common Stock. The Company's stockholders would retain the stock
certificates issued to them prior to the Effective Date, and those
certificates would continue to represent the number of shares evidenced
thereby. CERTIFICATES SHOULD NOT BE RETURNED TO THE COMPANY OR ITS TRANSFER
AGENT.
- -16-
<PAGE>
Amendment to the Certificate of Incorporation
If the Amendment is approved by the stockholders at the Annual Meeting of
Stockholders, Article Fourth of the Company's Certificate of Incorporation, as
amended, would read in full as follows:
"FOURTH: a) The Corporation shall be authorized to issue the following
shares of Capital Stock:
Class Number of Shares Par Value
Common Stock 50,000,000 $0.004
Preferred Stock 2,000,000 $0.01
b) The designations and the powers, preferences and rights, and the
qualifications or restrictions thereof are as follows:
The Preferred Stock shall be issued from time to time in one or more
series, with such distinctive serial designations as shall be stated and
expressed in the resolution or resolutions providing for the issue of such
shares from time to time adopted by the Board of Directors; and in such
resolution or resolutions providing for the issuance of shares of each
particular series, the Board of Directors is expressly authorized to fix the
annual rate or rates of the dividends for the particular series; the dividend
payment dates for the particular series and the date from which dividends on
all shares of such series issued prior to the record sate for the first
dividend payment shall be cumulative; the redemption price or prices for the
particular series; the voting powers for the particular series; the rights, if
any, of the holders of the shares of the particular series to convert the same
into share of any other series or class or other securities of the
corporation, with any provisions for the subsequent adjustment of such
conversion rights; and to classify or reclassify any unissued shares by fixing
or altering from time to time any of the foregoing rights, privileges and
qualifications.
All shares of Preferred Stock of any one series shall be identical with each
other in all respects, except that shares of any one series issued at
different times may differ as to the dates from which dividends thereon shall
be cumulative; and all Preferred Stock shall be of equal rank, regardless of
series, and shall be identical in all respects except as to the particulars
fixed by the Board as herinabove provided or as fixed herein.
Upon filing in the Office of the Secretary of State of the State of Delaware
of this Amendment to the Certificate of Incorporation, each currently issued
and outstanding share of Common Stock, par value $0.004 per share of the
Corporation shall be converted into two (2) shares of validly issued, fully
paid and non-assessable Common Stock, par value $0.004 per share of the
Corporation, and at the close of business on such date, each holder of record
of Common Stock shall, without further action, be and become the holder of one
additional share of Common Stock for each share of Common Stock held of record
immediately prior thereto."
Required Vote
The affirmative vote of a majority of the Company's outstanding shares of
Common Stock present or represented and entitled to vote at the 1998 Annual
Meeting of Stockholders is required to approve the Amendment to Certificate of
- -17-
<PAGE>
Incorporation effecting the Stock Split and increase in the number of
authorized shares. Abstentions as to this Proposal 2 will be treated as votes
against the Amendment to the Certificate. Broker non-votes, however, will be
treated as unvoted for purposes of determining approval of Proposal 2, and
thus will not be counted as votes for or against the Amendment to the
Certificate. Unless instructed to the contrary properly executed Proxies
will be voted FOR Proposal 2. Your Board of Directors recommends a vote FOR
approval of the amendment to effect the Stock Split and increase the
authorized number of shares of Common Stock.
3. Ratification of Selection of Auditors
The Board of Directors, following the recommendation of the Audit
Committee, has selected the independent public accounting firm of KPMG Peat
Marwick LLP as the auditors to examine the consolidated financial statements
of the Company for fiscal year 1999. The proxies solicited on behalf of the
Board of Directors will be voted to ratify selection of that firm unless
otherwise specified.
KPMG Peat Marwick LLP has served as the independent auditors for the
Company since 1994. Representatives of KPMG Peat Marwick LLP are expected to
be present at the Annual Meeting of Stockholders. They will have the
opportunity to make statements if they desire to do so and will be available
to respond to appropriate questions.
4. Other Business
The Board of Directors does not know of any other business to be
presented to the Annual Meeting of Stockholders. If any other matters properly
come before the meeting, however, the persons named in the enclosed form of
proxy will vote the proxy in accordance with their best judgment.
STOCKHOLDER PROPOSALS FOR 1999 ANNUAL MEETING
The Company expects to hold the 1999 Annual Meeting of Stockholders on
November 8, 1999. New Securities and Exchange Commission rules regarding
stockholder proposals became effective on June 29, 1998. If a stockholder
wishes to present a proposal at the 1999 Annual Meeting of Stockholders, the
proposal must be received by the Secretary of the Company on or before June 3,
1999, to be considered for inclusion in the Company's Proxy Statement and form
of proxy relating to the 1999 Annual Meeting of Stockholders. Pursuant to
these new rules if the Company has not received notice on or before August 20,
1999 of any matter a stockholder intends to propose for a vote at the 1999
Annual Meeting of Stockholders, then a proxy solicited by the Board of
Directors may be voted on such matter in the discretion of the proxy holder,
without discussion of the matter in the proxy statement soliciting such proxy
and without such matter appearing as a separate item on the proxy card.
By Order of the Board of Directors
Walter Flicker
Secretary
Dated: September 25, 1998
- -18-
<PAGE>
THIS PROXY IS SOLICITED BY AND ON BEHALF OF THE BOARD OF DIRECTORS OF
RESMED INC.
PROXY FOR 1998 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON NOVEMBER 6, 1998
The undersigned stockholder of ResMed Inc., a Delaware corporation, hereby
appoints each of Norman W. DeWitt and Walter Flicker, with full power to act
without the other and to appoint his substitute, as Proxy and attorney-in-fact
and hereby authorizes the Proxy to represent and to vote, as designated on the
reverse side, all the shares of voting stock of ResMed Inc., held of record by
the undersigned on September 8, 1998, at the 1998 Annual Meeting of
Stockholders to be held on November 6, 1998, or any adjournment or
postponement thereof.
This proxy, when properly executed, will be voted in the manner directed
herein by the undersigned stockholder. If this proxy is executed and no
direction is made, this proxy will be voted "FOR" the nominee listed under
proposal 1, "FOR" proposals 2 and 3 and as the Proxy deems advisable on such
other matters as may properly come before the meeting.
A majority of the proxies or substitutes who shall be present and shall act at
said meeting or any adjournments thereof (or if only one shall be present and
act, then that one) shall have and may exercise all of the powers of said
proxies hereunder.
PLEASE COMPLETE, DATE, SIGN AND RETURN
IN THE ENCLOSED ENVELOPE
(TO BE SIGNED ON REVERSE SIDE)
<PAGE>
[ X ] Please mark your votes as
in this example
FOR all WITHHOLDING AUTHORITY
nominees for only the following nominees
1. Election of
Director [ ] [ ] Mr Michael A Quinn
2. Approval of Amendment to FOR AGAINST ABSTAIN
Certificate of Incorporation
Effecting Stock Split and [ ] [ ] [ ]
Increasing the Authorized
Number of Shares of Common
Stock
FOR AGAINST ABSTAIN
3. Ratification of KPMG Peat Marwick LLP [ ] [ ] [ ]
as the auditors to examine the financial
statements of the Company for fiscal
year 1999.
The undersigned acknowledge receipt of the Notice of Meeting and Proxy
Statement dated September 25, 1998 and the 1998 Annual Report of the Company.
SIGNATURE(S): _______________________ DATE: ________________
SIGNATURE(S): _______________________ DATE: _________________
- -2-
